Is Ingevity Cheap After a 12% Buyback and a Return to Profit?

Buybacks made Ingevity look cheaper, but earnings quality still decides the valuation

On paper, Ingevity looks cheaper. In practice, part of that improvement comes from a smaller share count, not just a stronger income statement.

The recent earnings headline helped. Ingevity reported net income of US$35.3 million and returned to profitability versus a year-earlier loss. But the bigger change sits under the shares. The company also completed a $289.45 million repurchase that retired about 12.01% of outstanding stock since 2022. That means EPS can improve even if underlying earnings power only stabilizes.

Revenue quality is the other side of the debate. Reported net sales decreased 5%, but excluding Road Markings, sales increased 5%. Bulls can argue the core business is moving in the right direction and that each remaining share now captures more of it. Bears can argue the "cheap" label still depends heavily on a smaller denominator rather than clearly stronger demand.

Ingevity's buyback improved per-share math, but operating power improved too

A repurchase makes each share represent a larger slice of the business. The key question is whether the business itself also got better.

Per-share math versus operating improvement

In the latest quarter, Ingevity delivered adjusted earnings from continuing operations of $61.5 million and $1.74 of adjusted diluted EPS. More importantly, the underlying operating picture also improved: adjusted EBITDA from continuing operations reached $115.0 million, and adjusted EBITDA margin from continuing operations rose to 36.6% from 30.5% a year earlier.

That matters because a share buyback alone may only support EPS for a while. Durable gains in margin and profit from continuing operations are what make the remaining shares more valuable over time.

What the portfolio changes changed

The operating base is now different from what it was a year ago. Ingevity completed the sale of its Road Markings product line for approximately $63 million in net proceeds, and management raised full year Adjusted EBITDA outlook to a range of $380 to $400 million following a strong start to the year. That suggests the reset is not only about fewer shares; it is also about a different business mix.

The real test is whether that cleaner, more profitable base can hold long enough for investors to stop valuing Ingevity through the lens of its weaker historical period.

The valuation debate now is durability, not cleanup

The question is no longer whether Ingevity looks cleaner. It is whether the market is rerating the stock too quickly.

The bull case: the business can reprice as a better business

Bulls do not need the old story fully forgiven. They need the market to stop anchoring Ingevity to its weakest historical multiples. Management has been methodical: it completed its previously announced portfolio review, and it completed the sale of Performance Chemicals Road Markings product line after other portfolio actions earlier this year. At the same time, the company is exploring strategic alternatives for its Advanced Polymer Technologies segment, which keeps the possibility of a still cleaner earnings base alive.

That matters because a rerating usually takes more than one good quarter. It needs evidence that leadership can keep simplifying the business and improving margins. The latest quarter supported that case: adjusted earnings from continuing operations of $61.5 million and $1.74 of adjusted diluted EPS showed improvement after the buyback and portfolio changes. The run rate also improved earlier in the year, with Q1 net sales of $258.0 million up 4% and adjusted earnings from continuing operations of $41.4 million.

The bear case: cyclicality may still be underpriced

Bears argue the stock is being priced like a durable compounder before the cycle has fully proved itself. The core concern is straightforward: net sales still fell 5% in the latest quarter, even if underlying sales rose without Road Markings. That leaves room for investors to overstate how durable this turn really is.

What would confirm the thesis - and what would break it

Ingevity looks more interesting than a simple relief trade because the market still has to decide whether management's raised full year Adjusted EBITDA outlook to a range of $380 to $400 million marks a durable earnings base or merely a stronger pause after net sales decreased 5%.

What would confirm it

• Back-to-back quarters that support the $380 to $400 million full-year Adjusted EBITDA outlook, or push it higher.
• Continued investor acceptance of a lower reported sales line because mix and margins are improving, not just the share count.
• Further concrete action around Advanced Polymer Technologies after management completed its previously announced portfolio review.

What would break it

• Another quarter of weak reported sales without a similar EBITDA beat, which would suggest margins are doing most of the work.
• Continued delay on portfolio actions after management already said it completed its previously announced portfolio review and is exploring strategic alternatives.

For now, the cleaner setup is real. But whether Ingevity is truly cheap depends less on the buyback than on whether the new earnings base can hold.